Targeting the tumor vascular compartment to improve conventional cancer therapy

Trends in Pharmacological Sciences

Volumn 25, Issue 10, 2004, Pages 536-542

  Feron, Olivier ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; BLOCKING ANTIBODY; CELECOXIB; COMBRETASTATIN A1 PHOSPHATE; DALTEPARIN; ENDOSTATIN; ERLOTINIB; FLUNARIZINE; GEFITINIB; IMATINIB; LENALIDOMIDE; MONOCLONAL ANTIBODY LM 609; N ACETYLCOLCHINOL PHOSPHATE; NEUTRALIZING ANTIBODY; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REBIMASTAT; ROFECOXIB; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SUNITINIB; SURAMIN; THALIDOMID; THALIDOMIDE; TRASTUZUMAB; TUMSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VATALANIB; VERY LATE ACTIVATION ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 5;

ANGIOGENESIS; BLOOD VESSEL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; ENDOTHELIUM CELL; GENETIC STABILITY; HUMAN; INFORMATION PROCESSING; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 4544333732     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.08.008     Document Type: Review

References (43)

1. J. Folkman Tumor angiogenesis: therapeutic implications New Engl. J. Med. 285 1971 1182 1186
2. H. Hurwitz Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer New Engl. J. Med. 350 2004 2335 2342
3. H.F. Dvorak Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing New Engl. J. Med. 315 1986 1650 1659
4. R.S. Kerbel A cancer therapy resistant to resistance Nature 390 1997 335 336
5. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
6. A. Eberhard Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies Cancer Res. 60 2000 1388 1393
7. L.E. Benjamin Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J. Clin. Invest. 103 1999 159 165
8. M.S. Gee Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy Am. J. Pathol. 162 2003 183 193
9. R.M. Shaheen Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms Cancer Res. 61 2001 1464 1468
10. G. Bergers Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J. Clin. Invest. 111 2003 1287 1295
11. C.W. Song Modification in blood flow M. Molls P., Vaupel Blood Pefusion and Microenvironment of Human Tumors 1998 Springer-Verlag 193 207
12. B. Gallez Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry Magn. Reson. Med. 42 1999 627 630
13. P. Sonveaux Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery FASEB J. 16 2002 1979 1981
14. P. Sonveaux Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment Cancer Res. 64 2004 3209 3214
15. F. Paris Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice Science 293 2001 293 297
16. C. Lengauer Genetic instabilities in human cancers Nature 396 1998 643 649
17. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
18. R.S. Watnick Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis Cancer Cell 3 2003 219 231
19. R.S. Kerbel 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples Eur. J. Cancer 36 2000 1248 1257
20. P. Wachsberger Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction Clin. Cancer Res. 9 2003 1957 1971
21. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat. Med. 7 2001 987 989
22. R.K. Jain Molecular regulation of vessel maturation Nat. Med. 9 2003 685 693
23. C.G. Willett Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat. Med. 10 2004 145 147
24. B.J. Moeller Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules Cancer Cell 5 2004 429 441
25. P. Sonveaux Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy Cancer Res. 63 2003 1012 1019
26. S.M. Huang Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck Cancer Res. 59 1999 1935 1940
27. L. Milas In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin. Cancer Res. 6 2000 701 708
28. C.G. Lee Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res. 60 2000 5565 5570
29. T. Browder Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res. 60 2000 1878 1886
30. G. Klement Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J. Clin. Invest. 105 2000 R15 R24
31. G. Bocci Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy Proc. Natl. Acad. Sci. U. S. A. 100 2003 12917 12922
32. D.W. Siemann Targeting tumor blood vessels: an adjuvant strategy for radiation therapy Radiother. Oncol. 57 2000 5 12
33. P.E. Thorpe Vascular targeting agents as cancer therapeutics Clin. Cancer Res. 10 2004 415 427
34. P.E. Thorpe The first international conference on vascular targeting: meeting overview Cancer Res. 63 2003 1144 1147
35. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
36. G. Bergers Effects of angiogenesis inhibitors on multistage carcinogenesis in mice Science 284 1999 808 812
37. M. Relf Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res. 57 1997 963 969
38. J. Tran A role for survivin in chemoresistance of endothelial cells mediated by VEGF Proc. Natl. Acad. Sci. U. S. A. 99 2002 4349 4354
39. B. St Croix Genes expressed in human tumor endothelium Science 289 2000 1197 1202
40. X.S. Zhang Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165 Acta Pharmacol. Sin. 22 2001 731 735
41. T.G. Graeber Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours Nature 379 1996 88 91
42. J.L. Yu Effect of p53 status on tumor response to antiangiogenic therapy Science 295 2002 1526 1528
43. E.M. Hammond, and A.J. Giaccia Antiangiogenic therapy and p53 Science 297 2002 471